In a phase 2 decentralized study, once-daily trientine tetrahydrochloride improved convenience and adherence in Wilson disease; 80% preferred it.
|Articles|August 13, 2005
- August 2005
- Volume 22
- Issue 8
Representative cases from the ESTABLISH study
Advertisement
These figures show a representative case from each group in the ESTABLISH study. Baseline and follow-up IVUS images in both groups are presented; follow-up IVUS images are shown below the baseline images. Marked enlargement of the lumen and a decrease of plaque are clearly observed in the patient treated with atorvastatin at the non-PCI site after only 6 months of aggressive lipid-lowering therapy, whereas a significant reduction of the lumen and an increase of plaque are observed in the control patient.
Articles in this issue
about 21 years ago
Is mortality a function of age in congestive heart failure?about 21 years ago
Treatment of an 83-year-old man with congestive heart failureabout 21 years ago
Rate control in atrial fibrillationabout 21 years ago
Age and mortality in congestive heart failureabout 21 years ago
Early statin therapy in ACS: Reducing the burdenabout 21 years ago
Is early statin therapy effective in the acute coronary syndrome?about 21 years ago
Pulmonary arterial hypertension: A reviewabout 21 years ago
Preventing restenosis in diabetic patients with drug-eluting stentsAdvertisement
Related to this article
Type 2 biologics reduced mucus plugs in asthma trials, and quantitative imaging may help detect this treatable phenotype, according to a GOLD 2026 session.
In adults with late-onset PFIC, odevixibat improved pruritus within 3 months in a real-world study at presented at The Liver Meeting 2026.
CT-detected mucus plugs affect up to 67% of patients with COPD and are linked to worse lung function, exacerbations, and mortality, even without symptoms.
In patients with compensated MASH cirrhosis, Baveno VII and ANTICIPATE-NASH showed moderate agreement with HVPG and underestimated CSPH prevalence.
Robert Mentz, MD, discusses mentorship, trial recruitment, journal growth, and surgical partnerships in heart failure care.
At GOLD 2026, Alvar Agustí, MD, PhD, speaks on COPD underdiagnosis and misdiagnosis, barriers to spirometry in primary care, and managing pre-COPD.
In the phase 2b VISTAS trial, volixibat improved sleep vs placebo in PSC with cholestatic pruritus, and itch responders saw greater fatigue and sleep gains.
Advertisement
Advertisement
Trending on HCPLive
1
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
2
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
3
Conference Preview: 2026 GOLD International COPD Conference
4
Oral STAT6 Degrader KT-621 Reduces EASI by 62.6% in Atopic Dermatitis
5